Navigation Links
Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
Date:10/26/2007

discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, asthma and allergy and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.

Safe Harbor Statement

Certain statements in this news release concerning Coley's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Coley might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; uncertainties as to the future success of ongoing and planned clinical trials; the risk that results from early stage clinical trials may not be indicative of results in later stage trials; the unproven safety and efficacy of products under development; intellectual property rights and litigation; competitive products; and other risks identified in Coley's filings with the Securities and Exchange Commission including, but not limited to, Coley's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Coley undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or ot
'/>"/>

SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , MT. LAUREL, N.J., Nov. 30 /PRNewswire... leading provider of technology-enabled clinical d... this week at the Radiological Society of North Am...Q VTB for Radiology, the product leverages Speec... recognition application used by thousands of radi...
(Date:11/30/2009)..., , NEW YORK, Nov. 30 ...arch report is available in its catalogue: ,, ... Balance the Immune Response ,, http://www.re...rapies-That-Suppress-or-Balance-the-Immune-Respons... either attacking an individual body or producing ...
(Date:11/30/2009)..., , WALTHAM, Mass., Nov. 30 /PRNewswi...), the global authority on medical technology mark...cial injectable market declined by almost 5% over ...t as a result of the economic crisis. The market w... will return to the strong pre-recession growth ra...
Breaking Medicine Technology:MedQuist Features SpeechQ VTB for Radiology Solution at RSNA Convention 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 1Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 2Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 3Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 4Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 5Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 1Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 2Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 3Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 4Kensey Nash to Present at the JMP Securities Fourth Annual Healthcare Focus Conference 58495 1
...Va., Feb. 19 Innocoll, Inc., a privately-held,spe...second of two phase 3,clinical trials sponsored by...s Ltd, to investigate CollaRx(R) GENTAMICIN SURGIC...ections, has commenced dosing., GENTAMICIN SURGIC...surgical implant impregnated with the broad spectr...
...LL, N.C., Feb. 15 The landscape of scientific,pub...ing with the advent of,transparency guidelines. Ha... in the marketing function, but publications leade...linical presentation, according to a new,report re... study that included such influential companies as...
Other Medicine Technology:Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections 2Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections 3Industry Executives Finding Value in Shift of Scientific Publications 2
(Date:11/30/2009)...S, Nov. 30 The Eject Helmet Remova...ed equipment in the Top Fuel, Funny Car, Pro Stock...nal Hot Rod Association (NHRA) Full Throttle Drag ... and Top Alcohol Funny Car drivers in the NHRA Luc...duct that allows medical caregivers at race tracks...
(Date:11/30/2009)...note speaker & Author Dr. Temple Grandin to di... Corpus Christi, TX (Vocus) November 30, 2009 --... to be held in Corpus Christi from Thursday, Decem...erican Bank Center., , , , ,The conference will b...rly $300,000 economic impact on the city. The conf...
(Date:11/30/2009)... Nov. 30 Kemin Foods, L.C. ("Kemin...niActive Health Technologies, Ltd. ("OmniActive") ...te. The parties agree that Kemin,s US Patent No. 5...solation, Purification and Recrystallization of Lu...hereof" and the reissues of that patent are valid ...
(Date:11/30/2009)..., Nov. 30 Advanced Health Media, L...istics, speaker programs and commercial compliance...y, announced it has been named the second fastest ...s leading statewide business newspaper. AHM was h...e made significant contributions to the state,s gr...
(Date:11/30/2009)...et owner knows the enormous joy and comfort that a.... Most pets are considered important members of th...ody of research now documents the value of the hum... mental illness, physical impairment, dementia, ab... incarcerated youth and adults. , In two article...
Breaking Medicine News(10 mins):Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:18th Annual Texas Autism Conference Returns To Corpus Christi, Makes Nearly $300,000 Economic Impact 2Health News:Advanced Health Media Honored at NJ Finest Award Ceremony 2Health News:The therapeutic benefits of the human-animal bond 2
...May 29 Aging dental bridges are a maintenance,hea...are difficult to,floss, often decay, and require r...merican Academy of Implant Dentistry (AAID), these... They were put in at a time when bridgework was co...
...America (LFA) congratulates Annie and Tom of Chica...e NBC TODAY Show,s annual "Race to the,Altar." The... to be married,in June on the plaza outside the TO...ie was diagnosed with,lupus at age 17. Because lup...
...on Health & Science University Cancer Institute ab...f hope to many patients. , Researchers have discov... abnormalities that can occur in a gene called the...f skin cancer. Acral melanomas are found on the pa...
...estigators have shown that children under 3 years ...glioma (DPG) appear to have a better outcome than ... the study, which appear in the advance online pub...inicians had simply misdiagnosed the disease in ch...
...LLC, a,provider of clinically-useful applications ...,s largest enterprise software company, and Dell, ...utions, to bring the new,discoveries across health... By deploying the MedTrust Online Solution(TM), a ...
... would enable all Americans to have access to affo...y by the American College of Physicians (ACP). Th...lth Insurance Coverage for All Within Seven Years:...02 paper and said they remain, with some revisions...
Other Medicine News:Health News:Dental Implants Preferred Option for Aging Bridges 2Health News:Annie and Tom's Race to the Altar Inspires Lupus Community 2Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:St. Jude finds young age may give survival advantage to children with certain brain tumors 2Health News:MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery 2Health News:MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery 3Health News:ACP releases framework for policies enabling access to affordable health insurance coverage 2
Giardia lamblia II EIA
C. Diff-CHEK-60
NMP22 Bladder Cancer ELISA Test Kit
...re single-well ANA screen and ENA screen ELISAs, a...nd 6 individual ENA kits: Sm, Sm/RNP, SS-A (Ro), S...mune ELISA family includes a full line of products...Thyroid Microsomal, MPO, PR3, Rheumatoid Factor an...
Medicine Products: